Kornimate/medical-research-clean huggingface dataset:
online education to improve the management of rotator cuff related shoulder pain

Conditions: Subacromial Pain Syndrome; Rotator Cuff Injuries

Summary: a randomized controlled trial: conservative treatments including physiotherapy and rehabilitation in the management of rotator cuff-related shoulder pain (rcrsp) are generally accepted as the first-line treatment approach, however, it is known that the disease-specific physiotherapy methods used by physiotherapists are highly variable. this may be caused by the insufficient knowledge of therapists about evidence-based interventions to rcrsp. the aim of this study is to develop the '' rotator cuff related shoulder pain e-learning program'' and evaluate its effect on students' knowledge and clinical reasoning skills related to evidence-based rcrsp interventions and their levels of confidence to have this knowledge compared with a control group.

shoulder pain is one of society's most common musculoskeletal problems, with a prevalence defined between 16-26%. almost 70% of shoulder pain complaints are caused by pathologies associated with the rotator cuff. conservative treatments including physiotherapy are widely accepted as a first-line treatment approach in the management of shoulder pain and on the other hand, the variety of physiotherapy practice is conspicuous. despite the majority of physiotherapists provide treatment in line with current evidence, passive modalities are still highly preferred by some physiotherapists. the gap between research evidence and practice could be slightly due to the lack of an up-to-date undergraduate physiotherapy curriculum about the rcrsp. therefore, the aim of this study is to develop the '' rotator cuff related shoulder pain e-learning program'' and evaluate its effect on students' knowledge and clinical reasoning skills related to evidence-based rcrsp interventions and their levels of confidence to have this knowledge compared with a control group. a randomized controlled trial including 146 4th grade physiotherapy students will be conducted. students will be randomized into an e-learning group (n=73) or wait-list control group (n=73). the primary outcome will be the rcrsp achievement test, and the secondary outcome will be the self-reported confidence in knowledge and clinical reasoning skills related to rcrsp. all data will be collected through an online survey, which will be applied in two different time periods: pre-intervention and post-intervention. all groups will first answer the questionnaire at the beginning (week 0) and after the study group's e-learning activity (4-5 weeks).

Eligibility criteria:
inclusion criteria: * 3th or 4th grade physiotherapy students exclusion criteria: * students who are not currently enrolled in 3th or 4th grade

Keywords: online education shoulder pain physiotherapy
disturbed sleep model study.

Conditions: Sleep Initiation and Maintenance Disorders

Summary: subjects will be screened within 28 days. each treatment session will consist of 2 psg nights, study drug administration and noise model is conducted on second night.


Eligibility criteria:
inclusion criteria: * body weight =50 kg and bmi within the range 18.5-29.9 kg/m2 inclusive * healthy as judged by responsible physician. * no clinically significant abnormality identified on the medical or laboratory evaluation and 12-lead ecg; * the subject shows a normal sleep pattern on the basis of the evaluation of both psg screening nights. normal sleep will be defined as follows: lps (latency to persistence sleep) \ 85%, apnea/ hypopnea index \< 10, periodic leg movements (plm) with arousal index \< 10. the apnea/hypopnea index is defined as "the number of apneas and hyponeas divided by the total sleep time (tst) expressed in hours". plmi is defined as "the number of periodic leg movements associated with arousals or awakening divided by the total sleep time (tst) expressed in hour". exclusion criteria: * a positive result for the pre-study urine drug/ alcohol breath screen. * abuse of alcohol. * subject complains of sleep disturbances and /or is receiving treatment for sleep disorders.

Keywords: noise induced situational insomnia, healthy volunteers sb-649868, zolpidem,
transdermal basal insulin patch study in type 1 diabetes

Conditions: Type 1 Diabetes

Summary: this study is designed to evaluate the pharmacokinetics/pharmacodynamics of an investigational basal insulin patch in type 1 diabetes patients.

the study is looking for patients that meet the following criteria: * duration of type diabetes greater than or equal to 10 years * hba1c less than or equal to 9.0% * c-peptide negative * ages 18 - 65, male or female * body mass index (bmi) 18.5 - 32 * non-smoker * no advanced diabetes complications * not pregnant or breast feeding

Eligibility criteria:
inclusion criteria: * duration of type 1 diabetes greater than or equal to 10 years * hba1c less than or equal to 9.0% * c-peptide negative * ages 18 - 65, male or female * bmi 18.5 - 32 * non- smoker * no advance diabetes complications * not pregnant or breast feeding exclusion criteria: * arm or leg rashes, open wounds, or skin conditions * psychiatric disorders * participation in a clinical research trial in last 3 months * clinically significant acute illness

Keywords: diabetes insulin blood sugar type 1 diabetes insulin dependent diabetes transdermal
house dust mite treatment of asthma. the mitra trial house dust mite treatment of asthma

Conditions: Asthma

Summary: the purpose of this trial is to investigate if treatment with house dust mite allergen immunotherapy tablet can reduce the risk of asthma exacerbation in subjects with house dust mite induced asthma.


Eligibility criteria:
key inclusion criteria: * a clinical relevant history consistent with house dust mite induced asthma of at least 1 year prior to trial entry. * use of an appropriate amount of inhaled corticosteroid for the control of asthma symptoms. * documented reversible airway obstruction. * suitable level of asthma control. * fev1 ≥ 70% of predicted value. * positive skin prick test response to der pte and/or der far. * positive specific ige against der pte and/or der far (≥ ige class 2; ≥ 0.70 ku/l). key exclusion criteria: * a clinical history of persistent allergic asthma or rhinitis caused by an allergen to which the subject is regularly exposed and sensitised (except house dust mites). * a clinical history of intermittent allergic asthma or rhinitis if the seasonal allergen is causing symptoms in the period from october to march. * any clinically relevant chronic disease.

Keywords: hdm ait asthma asthma exacerbation house dust mite induced asthma
awake prone position in hypoxemic patients with coronavirus disease 19 covid-19 (covi-prone)

Conditions: Corona Virus Infection; Covid19; COVID-19

Summary: the aim of the covi-prone trial is to determine if early awake prone positioning in covid-19 patients with hypoxemic respiratory failure; irrespective of the mode of oxygen delivery; reduces the need for invasive mechanical ventilation.


Eligibility criteria:
inclusion criteria: 1. adults ≥ 18 years of age. 2. suspected or confirmed covid-19. defined as: a positive pcr for sars cov-2 or pending pcr results for patients that are suspected to have covid-19. 3. hypoxemia on room air (spo2\<90%), and oxygen requirement ≥ 0.4 fio2 (i.e. ≥ 40% oxygen). 4. bilateral or unilateral chest infiltrates on x-ray as interpreted by the treating team. 5. admitted to the icu or an acute care bed where hemodynamic and respiratory monitoring is feasible. exclusion criteria: 1. immediate need for intubation as determined by the treating team. 2. decreased level of consciousness (glasgow coma scale score \<10), or significant cognitive impairment hat may interfere with compliance (delirium, dementia) 3. contraindication to proning including, but not limited to any of the following: open chest or abdomen, abdominal surgery (i.e. laparotomy) within the 4 days, unstable spine, facial, cervical, femur, or pelvic fractures. limited neck mobility or inability to lie prone comfortably skeletal deformities that interfere with proning. complete bowel obstruction. active upper gastrointestinal bleeding. patient is unlikely/unable to prone, or to be compliant as indicated by the treating team. 4. body mass index \> 40 kg/m2 5. pregnancy - third trimester. 6. patient/substitute decision maker or caring physician's refusal to enroll in the study. 7. patients with hemodynamic instability and moderate to high dose of vasopressors (norepinephrine dose ≥ 0.15 mcg/kg/min) 8. intubation is not within patient's goals of care 9. patient received awake proning session for \> 1 day prior to randomization 10. previous intubation within the same hospital admission
erector spinae plane block versus intraarticular injection for postoperative analgesia in shoulder arthroscopy

Conditions: Shoulder Arthroscopy; Postoperative Analgesia; Erector Spinae Plane Block; Intraarticular Injection

Summary: to improve the outcome after surgery, effective pain control is needed. the aim of the current study was to compare the efficacy of ultrasound guided erector spinae plane block versus the intra articular injection of local anesthetic for post-operative analgesia in patients undergoing shoulder arthroscopy.

sample size calculation: calculation of sample size was done to detect a 15% difference in the vas score between two groups detected that at least 27 patients were needed at an α error of 0.05 and 80 % power of the study. the number will be increased to 30 patients to avoid a 10% dropped out patients. statistical analysis statistical analysis will be done by statistical package for the social sciences (spss) v25 (ibm inc., chicago, usa). normality of data will be checked with shapiro-wilks test and histogram. quantitative variables will be presented as mean and standard deviation (sd) and will be compared by unpaired student t test. categorical variables will be presented as frequency and percentage (%) and will be analysed by the chi-square test. p value \< 0.05 will be considered statistically significant.

Eligibility criteria:
inclusion criteria: * american society of anesthesiologists (asa) physical status i-ii * posted for elective shoulder arthroscopy exclusion criteria: * coagulopathy * allergy to local anesthetics * chronic use of narcotics * necessity for an intra articular drain after surgery * patients refusal to participate
the addition of dexmedetomidine on postoperative sleep for middle-aged and elderly patients with gastric cancer

Conditions: Gastric Cancer

Summary: the purpose of this study is to find out the effect of dexmedetomidine for treatment of sleep deprivation, pain relief and postoperative recovery on middle-aged and elderly patients with gastric cancer.

patients were randomized to receive sufentanil 0.05ug/kh/h + dexmedetomidine 0.1ug/kg/h (dex group) or sufentanil 0.05ug/kg/h + saline (control group) for 48h. the primary outcome was the total sleep time during the first three days after surgery. the secondary outcomes included pain score, daily sufentanil consumption, time to functional recovery, length of hospital stay and side effects.

Eligibility criteria:
inclusion criteria: elective gastric cancer operation age ≧ 55 years asa classification：i to iii, bmi: 18-30 kg/m2 without the history of gastrointestinal surgery the normal coagulation function - exclusion criteria: the history of gastrointestinal surgery gastrostomy and jejunostomy sleep apnea syndrome or severe osahs severe liver and heart dysfunction severe mental illness -

Keywords: dexmedetomidine sleep deprivation gastric cancer middle-aged and elderly patient
evaluation of ecallantide for treatment of angiotensin converting enzyme (ace) inhibitor induced angioedema

Conditions: ACE Inhibitor Induced Angioedema

Summary: a double-blind, randomized, controlled trial comparing the safety and effectiveness of conventional therapy with ecallantide to conventional therapy with placebo.


Eligibility criteria:
inclusion criteria: * males and females 18 years of age or older * must currently be on ace inhibitor therapy and have received a dose within 36 hours * presenting with aceia of the head/neck region within 12 hours after onset * all females must have a negative urine pregnancy test prior to administration of the study drug. those who have had a total hysterectomy, bilateral oophorectomy or are two years post-menopausal do not require a pregnancy test. exclusion criteria: * hypersensitivity to ecallantide * pregnancy or breast feeding * patients who have had angioedema and were not concurrently on an ace inhibitor * patients exhibiting urticaria * patients who are intubated or who have a tracheostomy related to the current episode of angioedema * opinion of the investigator that the patient would not be a good candidate * participation in another investigational study within 30 days prior to enrollment
intraoperative identification of parathyroid adenomas using pteye™ and fluobeam® lx: a prospective cohort study

Conditions: Primary Hyperparathyroidism Due to Adenoma

Summary: the goal of this observational study is to evaluate the efficacy of pteyetm device to confirm a parathyroid adenoma on a visually suspected tissue in comparison with the fluobeam®lx device. the main questions it aims to answer is: is the pteyetm device effective in identifying the presence of a parathyroid adenoma? which autofluorecence device (pteye or fluobeam®lx) is more effective in confirming the presence of a parathyroid adenoma? participants will undergo parathyroidectomy under general anesthesia. during the procedure visually suspected tissue for parathyroid adenoma will be evaluated with the pteye or fluobeam®lx device for the presence of an adenoma (minute 0). tissue will be reevaluated on minutes 1, 3, and 5 and before excision.

objective: pteye™ and fluobeam® lx use autofluorescence to confirm visually suspected parathyroid tissue. real-time intraoperative identification of parathyroid glands can be achieved by the application of both devices. the aim of the present study is to evaluate and compare the efficacy of pteye™ and fluobeam® lx in identifying parathyroid adenomas. methods: patients undergoing parathyroidectomy due to a parathyroid adenoma will be enrolled prospectively in this study and will be randomly included to group a (pteye™) or group b (fluobeam® lx). after intraoperative identification of parathyroid adenomas and before tissue dissection (minute 0), the efficacy of both devices to confirm the adenomas will be evaluated. re-evaluation will take place in minutes 1, 3 and 5 during tissue dissection and before adenoma excision.

Eligibility criteria:
inclusion criteria: - patients with primary parathyroidism with parathyroid adenoma exclusion criteria: * parathyroid hyperplasia, * secondary hyperparathyroidism
efficacy and tolerability of mlc601 in patients with mild to moderate alzheimer disease who were unable to tolerate or failed to benefit from treatment with rivastigmine

Conditions: Alzheimer Disease

Summary: current therapeutic approaches for the treatment of neurodegenerative diseases like alzheimer disease (ad) offer limited and often transient symptomatic benefits to patients but do not mitigate the insidious loss of neuronal cells. in this trial the investigators will evaluate efficacy and tolerability of mlc601 as a neuroprotective in patients with mild to moderate alzheimer disease who were unable to tolerate or failed to benefit from treatment with rivastigmine.

an 18-month open-label pilot study would be conducted at three university referral centres in tehran, iran. all patients are at least 50 years old, met the criteria for ad according to the fourth edition of the diagnostic and statistical manual of mental disorders (dsm-iv), and failed treatment with the cholinesterase inhibitor rivastigmine for any reason. a baseline medical history will be taken and physical examination will be performed for all participants, and any comorbidities and concomitant therapies would be noted. patients with controlled concomitant diseases, such as hypertension and diabetes, will be allowed to enter the study. mini-mental state examination (mmse)10 and alzheimer disease assessment scale-cognitive sub scale11 (adas-cog) will be used to measure treatment efficacy. mlc601 will be prescribed as one capsule three times daily without an escalation dose. safety and tolerability evaluations included physical examinations, electrocardiography, vital sign monitoring and laboratory testing weekly for the first 8 weeks and every 4 weeks thereafter. the mmse and adas-cog will be recorded at each efficacy follow-up visit.

Eligibility criteria:
inclusion criteria: * at least 50 years old * met the criteria for ad according to the fourth edition of the diagnostic and statistical manual of mental disorders (dsm-iv) * failed treatment with the cholinesterase inhibitor rivastigmine for any reason exclusion criteria: * uncontrolled diabetes mellitus * hypertension * unstable cardiac disease * severe obstructive pulmonary disease * renal or hepatic failure * and/or other life threatening conditions

Keywords: alzheimer disease cholinesterase inhibitors mlc601 neuroaid neuroprotection neuroregeneration
clinical audit on management of congenital heart disease in acuh

Conditions: Congenital Heart Disease

Summary: congenital heart disease (chd) is the most common birth defect in the united states, affecting approximately 0.8% of live births. improved treatment strategies and interventions have increased survival such that 85% to 90% of affected children are expected to live well into adulthood, thereby causing a demographic shift in which adults now outnumber children with chd, and more people with complex chd are living longer.

chd may be defined as an anatomic malformation of the heart or great vessels which occurs during intrauterine development, irrespective of the age at presentation. the cause of most congenital heart defects is still unknown. many cases of congenital heart disease are multifactorial and result from a combination of genetic predisposition and an environmental stimulus. a small percentage of congenital heart lesions are related to known chromosomal abnormalities, in particular, trisomy 21, 13, and 18 and turner syndrome. of all cases of congenital heart disease, 2-4% are associated with known environmental or adverse maternal conditions and teratogenic influences, including maternal diabetes mellitus, phenylketonuria, systemic lupus erythematosus or congenital rubella syndrome; and maternal ingestion of drugs (lithium, ethanol, warfarin, antimetabolites, vitamin a derivatives, anticonvulsant agents).

Eligibility criteria:
inclusion criteria: * children with chd more than one month exclusion criteria: * children with chd less than one month
comparison of triazolam and midazolam for anxiolysis during dental treatment in the pediatric patient

Conditions: Dental Anxiety

Summary: this study will evaluate the perceptions of the effects of two anxiolytic medications commonly used during dental treatment in patients weighing 40 kilograms or more.

midazolam and nitrous oxide are commonly used in pediatric patients requiring anxiolysis during dental treatment. triazolam and nitrous oxide are commonly used in adult patients requiring anxiolysis during dental treatment. the participants in this study are patients already scheduled for 2 sedation appointments to complete their dental treatment. the medications are both benzodiazepines that have similar risks, neither medication has greater adverse effects than the other. this study will evaluate the perceptions of the effects of the medications via a parent survey and chart review. the goal of the study is to determine which anxiolytic medication is perceived to provide a better sedation experience for older pediatric patients based on parent perception of the medication's effects and the patient's behavior during dental treatment.

Eligibility criteria:
inclusion criteria: 1. weigh 40 kilograms or more. 2. 2/4 or 3/4 frankl behavioral rating at their evaluation appointment. 3. dental treatment that requires two sedation appointments. dental treatment that requires sedation includes: fillings, crowns, pulpotomies and/or extractions. 4. between the ages of 7-17 years old. exclusion criteria: 1. patients taking any of the following medications will be excluded from the study: atripia, cimetidine, diltiazem, erythromycin, fluconazole, grapefruit juice, isoniazid, itraconazole, ketoconazole, nefazodone, rifampicin, ritonavir, fusidic acid, idelalisisb, methadone, olanzapine, thalidomide and/or troleandomycin. 2. pregnant patients will be excluded. 3. patients that have hiv-1 that is being treated with a protease inhibitor will be excluded. 4. patients with a mthfr mutation will be excluded. 5. patients with acute narrow angle glaucoma will be excluded. 6. patients that have had a previous adverse, paradoxical or allergic reaction to any benzodiazepines will be excluded from the study. 7. patients unable to swallow medication in tablet form. 8. patients that do not speak english as their primary language.
diagnostic procedures in detecting tumor cells in the bone marrow of patients undergoing surgery for stage i, stage ii, or stage iiia breast cancer

Conditions: Breast Cancer

Summary: rationale: diagnostic procedures that detect tumor cells in the bone marrow may help doctors predict disease recurrence and plan more effective treatment. purpose: this clinical trial is studying how well diagnostic procedures work in detecting tumor cells in the bone marrow of patients who have undergone surgery for stage i, stage ii, or stage iiia breast cancer.

objectives: primary * determine the relative risk of death associated with the presence of tumor cells in the bone marrow of patients with stage i, ii, or iiia breast cancer undergoing surgery and bone marrow analysis using multicolor fluorescence immunocytochemistry and bright field immunocytochemistry. secondary * compare multicolor fluorescence immunocytochemistry vs bright field immunocytochemistry in the detection of bone marrow micrometastases in these patients. outline: this is a multicenter study. patients undergo bone marrow aspiration during surgical resection of the primary tumor. bone marrow cells and tumor samples are analyzed using bright field immunocytochemistry and multicolor fluorescence immunocytochemistry. patients are followed every 12 months for up to 10 years. projected accrual: a total of 1,634 patients will be accrued for this study within 3 years.

Eligibility criteria:
inclusion criteria * histologic diagnosis of invasive adenocarcinoma of the breast diagnosed by core, incisional, or excisional biopsy. * all of the following staging criteria must be met: primary tumor must be operable and staged as ct1-3 by clinical evaluation. ipsilateral nodes must be cn0-1 by clinical evaluation. no evidence of metastatic disease (m0). exclusion criteria: * patients with any history of breast malignancy including dcis (patients with a history of lobular carcinoma in situ (lcis) are eligible). * treatment including radiation therapy, chemotherapy, and/or hormonal therapy administered for the currently diagnosed breast cancer prior to study entry. the only exception is hormonal therapy, which may have been given for up to a total of 28 days after diagnosis and before study entry. * patients who will be receiving preoperative chemotherapy. * bilateral malignancy (including dcis). * other non-breast malignancies unless the patient is considered disease-free for 5 years before study entry and is deemed by their physician to be at low risk for recurrence. patients with the following cancers are eligible if diagnosed and treated within the past 5 years: carcinoma in situ of the cervix, melanoma in situ, colon carcinoma in situ, and basal cell and squamous cell carcinoma of the skin.

Keywords: stage ia breast cancer stage ii breast cancer stage iiia breast cancer male breast cancer stage ib breast cancer